Pharmacokinetics and animal studies of rifapentine in tuberculosis

Nacer Lounis, Chantal Truffot-Pernot, Baohong Ji, Jacques Grosset

Research output: Contribution to journalArticle

Abstract

Rifapentine (RPT) is a long-acting rifamycin derivative which has a much longer half-life in mice and in humans than rifampicin (RIF). The minimal inhibitory concentration (MIC) of RPT against Mycobacterium tuberculosis is similar or slightly lower than that of RIF. The pharmacokinetics of rifapentine have been explored in both humans and mice and provided results more favorable for an intermittent treatment of tuberculosis than RIF and rifabutin (RBT). The activity of RPT against M. tuberculosis was better than that of RIF and RBT and was dose-related in both preventine and curative murine models of tuberculosis. RPT treatment administered once weekly was effective against M. tuberculosis but not when administered once every 2 or 3 weeks. An RPT-containing regimen was as effective as the daily standard regimen in the initial phase of treatment if it was preceded by 2 weeks of daily treatment containing RIF, isoniazid (INH), pyrazinamide (PZA) and streptomycin (SM) followed by a once-weekly regimen of RPT, INH, PZA and SM for 6 weeks RPT is a highly promising drug for intermittent therapy of tuberculosis.

Original languageEnglish (US)
Pages (from-to)17-27
Number of pages11
JournalDrugs of Today
Volume35
Issue numberSUPPL. D
StatePublished - 1999
Externally publishedYes

Fingerprint

rifapentine
Tuberculosis
Pharmacokinetics
Rifampin
Mycobacterium tuberculosis
Rifabutin
Pyrazinamide
Streptomycin
Isoniazid
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Lounis, N., Truffot-Pernot, C., Ji, B., & Grosset, J. (1999). Pharmacokinetics and animal studies of rifapentine in tuberculosis. Drugs of Today, 35(SUPPL. D), 17-27.

Pharmacokinetics and animal studies of rifapentine in tuberculosis. / Lounis, Nacer; Truffot-Pernot, Chantal; Ji, Baohong; Grosset, Jacques.

In: Drugs of Today, Vol. 35, No. SUPPL. D, 1999, p. 17-27.

Research output: Contribution to journalArticle

Lounis, N, Truffot-Pernot, C, Ji, B & Grosset, J 1999, 'Pharmacokinetics and animal studies of rifapentine in tuberculosis', Drugs of Today, vol. 35, no. SUPPL. D, pp. 17-27.
Lounis N, Truffot-Pernot C, Ji B, Grosset J. Pharmacokinetics and animal studies of rifapentine in tuberculosis. Drugs of Today. 1999;35(SUPPL. D):17-27.
Lounis, Nacer ; Truffot-Pernot, Chantal ; Ji, Baohong ; Grosset, Jacques. / Pharmacokinetics and animal studies of rifapentine in tuberculosis. In: Drugs of Today. 1999 ; Vol. 35, No. SUPPL. D. pp. 17-27.
@article{cbf0454d6267491e8cb3954046573846,
title = "Pharmacokinetics and animal studies of rifapentine in tuberculosis",
abstract = "Rifapentine (RPT) is a long-acting rifamycin derivative which has a much longer half-life in mice and in humans than rifampicin (RIF). The minimal inhibitory concentration (MIC) of RPT against Mycobacterium tuberculosis is similar or slightly lower than that of RIF. The pharmacokinetics of rifapentine have been explored in both humans and mice and provided results more favorable for an intermittent treatment of tuberculosis than RIF and rifabutin (RBT). The activity of RPT against M. tuberculosis was better than that of RIF and RBT and was dose-related in both preventine and curative murine models of tuberculosis. RPT treatment administered once weekly was effective against M. tuberculosis but not when administered once every 2 or 3 weeks. An RPT-containing regimen was as effective as the daily standard regimen in the initial phase of treatment if it was preceded by 2 weeks of daily treatment containing RIF, isoniazid (INH), pyrazinamide (PZA) and streptomycin (SM) followed by a once-weekly regimen of RPT, INH, PZA and SM for 6 weeks RPT is a highly promising drug for intermittent therapy of tuberculosis.",
author = "Nacer Lounis and Chantal Truffot-Pernot and Baohong Ji and Jacques Grosset",
year = "1999",
language = "English (US)",
volume = "35",
pages = "17--27",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "SUPPL. D",

}

TY - JOUR

T1 - Pharmacokinetics and animal studies of rifapentine in tuberculosis

AU - Lounis, Nacer

AU - Truffot-Pernot, Chantal

AU - Ji, Baohong

AU - Grosset, Jacques

PY - 1999

Y1 - 1999

N2 - Rifapentine (RPT) is a long-acting rifamycin derivative which has a much longer half-life in mice and in humans than rifampicin (RIF). The minimal inhibitory concentration (MIC) of RPT against Mycobacterium tuberculosis is similar or slightly lower than that of RIF. The pharmacokinetics of rifapentine have been explored in both humans and mice and provided results more favorable for an intermittent treatment of tuberculosis than RIF and rifabutin (RBT). The activity of RPT against M. tuberculosis was better than that of RIF and RBT and was dose-related in both preventine and curative murine models of tuberculosis. RPT treatment administered once weekly was effective against M. tuberculosis but not when administered once every 2 or 3 weeks. An RPT-containing regimen was as effective as the daily standard regimen in the initial phase of treatment if it was preceded by 2 weeks of daily treatment containing RIF, isoniazid (INH), pyrazinamide (PZA) and streptomycin (SM) followed by a once-weekly regimen of RPT, INH, PZA and SM for 6 weeks RPT is a highly promising drug for intermittent therapy of tuberculosis.

AB - Rifapentine (RPT) is a long-acting rifamycin derivative which has a much longer half-life in mice and in humans than rifampicin (RIF). The minimal inhibitory concentration (MIC) of RPT against Mycobacterium tuberculosis is similar or slightly lower than that of RIF. The pharmacokinetics of rifapentine have been explored in both humans and mice and provided results more favorable for an intermittent treatment of tuberculosis than RIF and rifabutin (RBT). The activity of RPT against M. tuberculosis was better than that of RIF and RBT and was dose-related in both preventine and curative murine models of tuberculosis. RPT treatment administered once weekly was effective against M. tuberculosis but not when administered once every 2 or 3 weeks. An RPT-containing regimen was as effective as the daily standard regimen in the initial phase of treatment if it was preceded by 2 weeks of daily treatment containing RIF, isoniazid (INH), pyrazinamide (PZA) and streptomycin (SM) followed by a once-weekly regimen of RPT, INH, PZA and SM for 6 weeks RPT is a highly promising drug for intermittent therapy of tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=0033408541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033408541&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033408541

VL - 35

SP - 17

EP - 27

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - SUPPL. D

ER -